|
|
2%克立硼罗软膏治疗轻中度特应性皮炎安全性和有效性的Meta分析
|
Abstract:
目的：系统性评价2%克立硼罗(Crisaborole)软膏治疗轻中度特应性皮炎(AD)的有效性与安全性。方法：检索中国知网、维普、万方、Embase、Cochrane Library、PubMed和ClinicalTrials.gov 7个数据库，从其中筛选出有关2%克立硼罗软膏治疗轻中度特应性皮炎的临床研究。对相关研究进行数据筛选和偏倚风险评估。使用RevMan5.4软件对筛选出的数据进行系统性荟萃分析。结果：7项随机对照临床试验被筛选入该项研究中，共包括2174例AD患者。Meta分析结果显示，2%克立硼罗治疗特应性皮炎的疗效优于赋形剂具有统计学意义。外用2%克立硼罗软膏的不良反应及严重不良反应发生率与赋形剂相比，其差异没有统计学意义。结论：2%克立硼罗软膏用于治疗轻中度特应性皮炎有效性良好。2%克立硼罗软膏的安全性良好。
Objective: To systematically evaluated the safety and efficacy of 2% Crisaborole ointment in the treatment of mild to moderate atopic dermatitis (AD). Methods: Seven databases including China National Knowledge Infrastructure, VIP Database for Chinese Technical Periodicals, Wanfang data-base, Embase, CochraneLibrary, PubMed and ClinicalTrials.Gov. were searched to screen out clinical studies related to clariborol in the treatment of atopic dermatitis, and data extraction and bias risk assessment were conducted for the selected studies. Finally, a systematic meta-analysis of the ex-tracted data was conducted using RevMan5.4 software. Results: Seven randomized controlled clini-cal trials were screened for the study, involving a total of 2174 patients with AD. The results of the meta-analysis showed that the efficacy of 2% creborol in the treatment of atopic dermatitis was sta-tistically superior to excipients. There was no statistical significance in the incidence of adverse re-actions and serious adverse reactions of 2% creborol ointment compared with excipients. Conclu-sion: 2% Crisaborole ointment is effective for the treatment of mild to moderate AD. The safety of 2% Crisaborole ointment is good.
| [1] | Weidinger, S., Beck, L.A., Bieber, T., Kabashima, K. and Irvine, A.D. (2018) Atopic Dermatitis. Nature Reviews Disease Primers, 4, Article No. 1. https://doi.org/10.1038/s41572-018-0001-z |
| [2] | Frazier, W. and Bhardwaj, N. (2020) Atopic Dermatitis: Diagnosis and Treatment. American Family Physician, 101, 590-598. |
| [3] | 齐雨婷, 靳清清, 陈果, 等. 抗IL-13抗体治疗中重度特应性皮炎疗效与安全性的荟萃分析[J]. 中国免疫学杂志. 2022, 38(6): 738-744. |
| [4] | Sroka-Tomaszewska, J. and Trzeciak, M. (2021) Molecular Mechanisms of Atopic Dermatitis Pathogen-esis. International Journal of Molecular Sciences, 22, Article 4130. https://doi.org/10.3390/ijms22084130 |
| [5] | Tominaga, M. and Takamori, K. (2022) Peripheral Itch Sensitization in Atopic Dermatitis. Allergology International, 71, 265-277. https://doi.org/10.1016/j.alit.2022.04.003 |
| [6] | Silverberg, J.I., Garg, N.K., Paller, A.S., Fishbein, A.B. and Zee, P.C. (2015) Sleep Disturbances in Adults with Eczema Are Associated with Impaired Overall Health: A US Popula-tion-Based Study. The Journal of Investigative Dermatology, 135, 56-66. https://doi.org/10.1038/jid.2014.325 |
| [7] | Sacotte, R. and Silverberg, J.I. (2018) Epidemiology of Adult Atopic Dermatitis. Clinics in Dermatology, 36, 595-605.
https://doi.org/10.1016/j.clindermatol.2018.05.007 |
| [8] | Barbarot, S., Silverberg, J.I., Gadkari, A., et al. (2022) The Family Impact of Atopic Dermatitis in the Pediatric Population: Results from an International Cross-Sectional Study. The Journal of Pediatrics, 246, 220-226.
https://doi.org/10.1016/j.jpeds.2022.04.027 |
| [9] | Ali, F., Vyas, J. and Finlay, A.Y. (2020) Counting the Burden: Atopic Dermatitis and Health-Related Quality of Life. Acta Dermato-Venereologica, 100, 330-340. https://doi.org/10.2340/00015555-3511 |
| [10] | Salvati, L., Cosmi, L. and Annunziato, F. (2021) From Emollients to Biologicals: Targeting Atopic Dermatitis. International Journal of Molecular Sciences, 22, Article 10381. https://doi.org/10.3390/ijms221910381 |
| [11] | Lin, T.K., Zhong, L. and Santiago, J.L. (2017) Association between Stress and the HPA Axis in the Atopic Dermatitis. International Journal of Molecular Sciences, 18, Article 2131. https://doi.org/10.3390/ijms18102131 |
| [12] | Paller, A., Kabashima, K., Bieber, T., et al. (2017) Therapeutic Pipeline for Atopic Dermatitis: End of the Drought? 140, 633-643. https://doi.org/10.1016/j.jaci.2017.07.006 |
| [13] | Singh, I., Chat, V.S., Uy, A., et al. (2022) Who Sees You Matters: A Population Study Examining Topical Corticosteroid Pre-scribing Patterns between Primary Care Providers and Dermatologists for Atopic Dermatitis. The Journal of Dermato-logical Treatment, 33, 1507-1510. https://doi.org/10.1080/09546634.2020.1836311 |
| [14] | Eichenfield, L., Tom, W., Berger, T., et al. (2014) Guidelines of Care for the Management of Atopic Dermatitis: Section 2. Management and Treatment of Atopic Dermatitis with Topical Therapies. Journal of the American Academy of Dermatology, 71, 116-132. |
| [15] | Ramachandran, V., Cline, A., Feldman, S. and Strowd, L.C. (2019) Evaluating Crisaborole as a Treatment Option for Atopic Dermatitis. Expert Opinion on Pharmacotherapy, 20, 1057-1063.
https://doi.org/10.1080/14656566.2019.1604688 |
| [16] | 梁龙铭. 磷酸二酯酶4抑制剂ZL-n-91对三阴性乳腺癌的治疗作用及机制研究[D]: [硕士学位论文]. 广州: 广东工业大学, 2022. |
| [17] | 王惠芳, 王有志, 支运宝, 等. 磷酸二酯酶4抑制剂临床及安全性研究进展[J]. 药学学报, 1-13. |
| [18] | Lugnier, C. (2022) The Complexity and Multi-plicity of the Specific cAMP Phosphodiesterase Family: PDE4, Open New Adapted Therapeutic Approaches. Interna-tional Journal of Molecular Sciences, 23, Article 10616.
https://doi.org/10.3390/ijms231810616 |
| [19] | Jarnagin, K., Chanda, S., Coronado, D., et al. (2016) Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Develop-ment for the Treatment of Atopic Dermatitis. Journal of Drugs in Dermatology: JDD, 15, 390-396. |
| [20] | 王洁, 金珊, 朱莲花, 等. 外用磷酸二酯酶4抑制剂在特应性皮炎中的研究进展[J]. 中国皮肤性病学杂志[J]. 2022, 36(10): 1216-1220. |
| [21] | Zane, L., Kircik, L., Call, R., et al. (2016) Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study. Pediatric Dermatology, 33, 380-387. https://doi.org/10.1111/pde.12872 |
| [22] | Tom, W., Van Syoc, M., Chanda, S., et al. (2016) Pharmaco-kinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study. Pediatric Dermatology, 33, 150-159. https://doi.org/10.1111/pde.12780 |
| [23] | Paller, A., Tom, W., Lebwohl, M., et al. (2016) Efficacy and Safety of Crisaborole Ointment, a Novel, Nonsteroidal Phos-phodiesterase 4 (PDE4) Inhibitor for the Topical Treatment of Atopic Dermatitis (AD) in Children and Adults. Journal of the American Academy of Dermatology, 75, 494-503. https://doi.org/10.1016/j.jaad.2016.05.046 |
| [24] | Bissonnette, R., Pavel, A., Diaz, A., et al. (2019) Crisaborole and Atopic Dermatitis Skin Biomarkers: An Intrapatient Randomized Trial. Journal of Allergy and Clinical Immunology, 144, 1274-1289.
https://doi.org/10.1016/j.jaci.2019.06.047 |
